Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

Impact of Therapy Sequence on Survival Outcomes Among Patients with Relapsed or Refractory Mature T and NK Cell Neoplasms: A Global Retrospective Cohort Study

Mark N Sorial, Min Jung Koh, Leora Boussi, Jessy Xinyi Han, Luke Peng, Ijeoma Julie Eche-Ugwu, Rui Duan, Matthew M. Lei, Eliana Miranda, Carlos Chiattone, Robert Stuver, Steven M. Horwitz, Maria J. Fernandez Turizo, Sean McCabe, Mwanasha Hamuza Merrill, Eric Jacobsen, Jin Seok Kim, Yu Ri Kim, Jae Yong Cho, Hasmukh Jain, Manju Sengar, Thomas Eipe, Tanuja Shet, Shambhavi Singh, Uvette Lou, Hesham Raghib, Judith Gabler, Min Ji Koh, Carrie Van Der Weyden, Miles Prince, Ramzi Hamouche, Tinatin Muradashvili, Francine M. Foss, Marianna Gentilini, Beatrice Casadei, Pier Luigi Zinzani, Takeshi Okatani, Noriaki Yoshida, Sang Eun Yoon, Won Seog Kim, Girisha Panchoo, Zainab Mohamed, Estelle Verburgh, Jackielyn Cuenca Alturas, Mubarak Al Mansour, Josie Ford, Martina Manni, Massimo Federico, Owen A. O'Connor, Maria Elena Cabrera, Enrica Marchi, Changyu Shen, Devavrat Shah, Salvia Jain

Blood (2023) 142 (Supplement 1): 3080.

https://doi.org/10.1182/blood-2023-182341

Published: 2023

Journal Articles

High Efficacy and Excellent Safety Profile of Actalycabtagene Autoleucel, a Humanized CD19 CAR-T Product in r/r B-Cell Malignancies: A Phase II Pivotal Trial

Blood (2023) 142 (Supplement 1): 4838.

https://doi.org/10.1182/blood-2023-185507

Published: 2023

Journal Articles

Real-World Outcomes with Intensive Chemotherapy in Acute Myeloid Leukemia Patients Deemed “Unfit” for Remission Induction By Landmark Trials' Criteria

Thomas Eipe, Hasmukh Jain, Manju Sengar, Bhausaheb Bagal, Lingaraj Nayak, Alok Shetty

Blood (2023) 142 (Supplement 1): 2442.

https://doi.org/10.1182/blood-2023-188787

Published: 2023

Journal Articles

Patterns of Care and Outcome in Adolescent and Young Adults (AYA) Lymphomas- a Multicenter HCC (Hematologic Cancer Consortium) Registry Study from India

Lingaraj Nayak, Sushil Selvarajan, Hasmukh Jain, Parathan Karunakaran, Prasanth Ganesan, Jayachandran Perumal Kalaiyarasi, Nikita Mehra, Anu Korula, Uday Kulkarni, Aby Abraham, Alok Parekh, Ritam Joarder, Santhosh Kumar Devadas, Jina Bhattacharyya, Dubashi Biswajit, Vineetha Raghavan, Mobin Paul

Blood (2023) 142 (Supplement 1): 2412.

https://doi.org/10.1182/blood-2023-185774

Published: 2023

Journal Articles

Outcomes of Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia: An Indian Multi-Institution, Prospective Study from the Haematology Cancer Consortium (HCC)

Prasanth Ganesan, Mehak Trikha, Hasmukh Jain, Uday Prakash Kulkarni, Sushil Selvarajan, Anu Korula, Parathan Karunakaran, Smitha Carol Saldanha, Smita Kayal, Sadashivudu Gundeti, Gaurav Chatterjee, Praveen Kumar Shenoy, Dhanlaxmi Lalit Shetty, Rajan Kapoor, Rasmi Palassery, Mobin Paul, Om Prakash, Maya P Ganesan, Prasanna Samuel

Blood (2023) 142 (Supplement 1): 5821.

https://doi.org/10.1182/blood-2023-186743

Published: 2023

Journal Articles

Novel Causal Inference Method Estimates Treatment Effects of Contemporary Drugs in a Global Cohort of Patients with Relapsed and Refractory Mature T-Cell and NK-Cell Neoplasms

Blood (2023) 142 (Supplement 1): 1703.

https://doi.org/10.1182/blood-2023-185881

Published: 2023

Journal Articles

Outcomes in Routine Clinical Practice with Methotrexate-Temozolomide-Rituximab Induction and Modified Etoposide-Cytarabine Consolidation in Newly Diagnosed Primary CNS Lymphoma

Blood (2023) 142 (Supplement 1): 987.

https://doi.org/10.1182/blood-2023-186742

Published: 2023

Journal Articles

Hepatitis B Reactivation without Hepatitis Is a Common Event in Adolescent/Adult Patients of Acute Lymphoblastic Leukemia with Occult Hepatitis B (OHBI) Treated on Pediatric Protocols and Warrants Prophylactic Antivirals: A Prospective Cohort Study

Devanshee Shah, Hasmukh Jain, Prachi Patil, Netra Ghandade, Sanjay Biswas, Gaurav Salunkhe, Lingaraj Nayak, Bhausaheb Bagal, Neha Sharma, Manju Sengar

Blood (2023) 142 (Supplement 1): 1459.

https://doi.org/10.1182/blood-2023-181038

Published: 2023

Journal Articles

Excellent Safety Profile of a Low-Cost Novel Humanized CD19 CAR T-Cell Therapy, Actalycabtagene Autoleucel : Potential Impact on Access and Feasibility

Blood (2023) 142 (Supplement 1): 257.

https://doi.org/10.1182/blood-2023-177594

Published: 2023

Journal Articles

Outcomes and Prognostic Factors in Patients with Primary Mediastinal B Cell Lymphoma: An Experience from Hematology Cancer Consortium

Akhil Rajendra, Alok Shetty, Anu Korula, Hasmukh Jain, Mobin Paul, Prasanth Ganesan, Jayachandran Perumal Kalaiyarasi, Santhosh Kumar Devadas, Sushil Selvarajan, Abhilash Menon, Divya K, Parathan Karunakaran, Lingaraj Nayak, Om Prakash, Bhausaheb Bagal, Aby Abraham, Prasanna Samuel, Uday Kulkarni

Blood (2023) 142 (Supplement 1): 3141.

https://doi.org/10.1182/blood-2023-186670

Published: 2023

Journal Articles

E valuating the S afety of HCAR19 (Now Actalycabtagene Autoleucel- Actaly-Cel™), a Novel H umanized CD19-Directed Chimeric Antigen Receptor T-Cells in Pediatric, Adolescents, and Young Adults with Relapsed/ Refractory B- Acute Lymphoblastic Leukemia (ESHA) - Report of Phase-1B

Blood (2023) 142 (Supplement 1): 6878.

https://doi.org/10.1182/blood-2023-180867

Published: 2023

Journal Articles

Serum microRNA Signature Predicting Poor Therapeutic Response to Bortezomib-Based Therapy and Clinical Outcome in Newly Diagnosed Multiple Myeloma: A Result of miRNA Profiling By Deep Sequencing

Blood (2022) 140 (Supplement 1): 4292–4293.

https://doi.org/10.1182/blood-2022-168598

Published: 2022

Journal Articles

Prognostic Factors and Outcomes of Adolescent and Adult Burkitt Lymphoma and Leukemiafrom a Low-Middle Income Country: An Experience from Hematology Cancer Consortium

Blood (2022) 140 (Supplement 1): 6687–6689.

https://doi.org/10.1182/blood-2022-165840

Published: 2022

Journal Articles

Real World Data on Unique Challenges and Outcomes of Older Patients with AML from Resource Limited Settings: Indian Acute Leukemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC)

Blood (2022) 140 (Supplement 1): 6096–6098.

https://doi.org/10.1182/blood-2022-167099

Published: 2022

Journal Articles

Induction Related Mortality Score in Acute Myeloid Leukemia: Prospective Validation Study (pRISM) of the Hematology Cancer Consortium (HCC)

Blood (2022) 140 (Supplement 1): 3223–3224.

https://doi.org/10.1182/blood-2022-169001

Published: 2022

Journal Articles

Circulating Clonal Plasma Cells at Diagnosis and Peripheral Blood Measurable Residual Disease Assessment Provide Powerful Prognostication Biomarkers in Newly-Diagnosed Multiple Myeloma Patients Treated without Autologous Transplant

Blood (2022) 140 (Supplement 1): 1135–1136.

https://doi.org/10.1182/blood-2022-165715

Published: 2022

Journal Articles

Making Anti-CD19 CAR-T Cell Therapy Accessible and Affordable: First-in-Human Phase I Clinical Trial Experience from India

Blood (2022) 140 (Supplement 1): 4610–4611.

https://doi.org/10.1182/blood-2022-168928

Published: 2022

Journal Articles

Low Dose Dasatinib Is Not As Active in a CML CP Cohort Enriched with Intermediate/High-Risk CML Chronic Phase: A Phase IIb Multi-Center Trial

Blood (2022) 140 (Supplement 1): 6789–6790.

https://doi.org/10.1182/blood-2022-169777

Published: 2022

Journal Articles

Real-World Outcomes for Acute Promyelocytic Leukemia: Need to Address Induction Mortality

Manju Sengar, Hasmukh Jain, Uday Prakash Kulkarni, Vasu Babu Goli, Anu Korula, Prasanna Samuel, Sushil Selvarajan, Lingaraj Nayak, Aby Abraham, Om Prakash, Fouzia N., Saranya Kumaran, Jayashree Thorat, Bhausaheb Bagal, Poonkuzhali Balasubramanian, Dhanlaxmi Shetty, Nikhil Patkar, Biju George, Vikram Mathews

Blood (2022) 140 (Supplement 1): 3244–3245.

https://doi.org/10.1182/blood-2022-167202

Published: 2022

Journal Articles

Acute Myeloid Leukemia during the COVID Pandemic: Impact and the Indian Experience

Blood (2022) 140 (Supplement 1): 8127–8128.

https://doi.org/10.1182/blood-2022-165770

Published: 2022

NARROW

Impact of Therapy Sequence on Survival Outcomes Among Patients with Relapsed or Refractory Mature T and NK Cell Neoplasms: A Global Retrospective Cohort Study

High Efficacy and Excellent Safety Profile of Actalycabtagene Autoleucel, a Humanized CD19 CAR-T Product in r/r B-Cell Malignancies: A Phase II Pivotal Trial

Real-World Outcomes with Intensive Chemotherapy in Acute Myeloid Leukemia Patients Deemed “Unfit” for Remission Induction By Landmark Trials' Criteria

Patterns of Care and Outcome in Adolescent and Young Adults (AYA) Lymphomas- a Multicenter HCC (Hematologic Cancer Consortium) Registry Study from India

Outcomes of Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia: An Indian Multi-Institution, Prospective Study from the Haematology Cancer Consortium (HCC)

Novel Causal Inference Method Estimates Treatment Effects of Contemporary Drugs in a Global Cohort of Patients with Relapsed and Refractory Mature T-Cell and NK-Cell Neoplasms

Outcomes in Routine Clinical Practice with Methotrexate-Temozolomide-Rituximab Induction and Modified Etoposide-Cytarabine Consolidation in Newly Diagnosed Primary CNS Lymphoma

Hepatitis B Reactivation without Hepatitis Is a Common Event in Adolescent/Adult Patients of Acute Lymphoblastic Leukemia with Occult Hepatitis B (OHBI) Treated on Pediatric Protocols and Warrants Prophylactic Antivirals: A Prospective Cohort Study

Excellent Safety Profile of a Low-Cost Novel Humanized CD19 CAR T-Cell Therapy, Actalycabtagene Autoleucel : Potential Impact on Access and Feasibility

Outcomes and Prognostic Factors in Patients with Primary Mediastinal B Cell Lymphoma: An Experience from Hematology Cancer Consortium

E valuating the S afety of HCAR19 (Now Actalycabtagene Autoleucel- Actaly-Cel™), a Novel H umanized CD19-Directed Chimeric Antigen Receptor T-Cells in Pediatric, Adolescents, and Young Adults with Relapsed/ Refractory B- Acute Lymphoblastic Leukemia (ESHA) - Report of Phase-1B

Serum microRNA Signature Predicting Poor Therapeutic Response to Bortezomib-Based Therapy and Clinical Outcome in Newly Diagnosed Multiple Myeloma: A Result of miRNA Profiling By Deep Sequencing

Prognostic Factors and Outcomes of Adolescent and Adult Burkitt Lymphoma and Leukemiafrom a Low-Middle Income Country: An Experience from Hematology Cancer Consortium

Real World Data on Unique Challenges and Outcomes of Older Patients with AML from Resource Limited Settings: Indian Acute Leukemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC)

Induction Related Mortality Score in Acute Myeloid Leukemia: Prospective Validation Study (pRISM) of the Hematology Cancer Consortium (HCC)

Circulating Clonal Plasma Cells at Diagnosis and Peripheral Blood Measurable Residual Disease Assessment Provide Powerful Prognostication Biomarkers in Newly-Diagnosed Multiple Myeloma Patients Treated without Autologous Transplant

Making Anti-CD19 CAR-T Cell Therapy Accessible and Affordable: First-in-Human Phase I Clinical Trial Experience from India

Low Dose Dasatinib Is Not As Active in a CML CP Cohort Enriched with Intermediate/High-Risk CML Chronic Phase: A Phase IIb Multi-Center Trial

Real-World Outcomes for Acute Promyelocytic Leukemia: Need to Address Induction Mortality

Acute Myeloid Leukemia during the COVID Pandemic: Impact and the Indian Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only